Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis
Our findings suggest that RT combined with YM101 enhances antitumor immunity and overcomes resistance in non-inflamed tumors in preclinical models, while simultaneously showing potential in mitigating RT-induced fibrosis. This combination therapy demonstrates promise in overcoming ICI resistance, while potentially sparing normal pulmonary tissue, thereby providing a strong rationale for further clinical investigations.
Authors
- Binghan Zhou
- Kongming Wu (ORCID: https://orcid.org/0000-0003-2499-1032)
- Qi Mei (ORCID: https://orcid.org/0000-0002-9826-5044)
- Mengke Niu
- Ming Yi (ORCID: https://orcid.org/0000-0001-5243-6613)
- Yuze Wu (ORCID: https://orcid.org/0000-0002-7344-6623)
- Pengfei Zhou (ORCID: https://orcid.org/0000-0003-2181-3804)
- Yarong Guo (ORCID: https://orcid.org/0000-0002-3589-5882)
- Jing Zhang (ORCID: https://orcid.org/0000-0002-0137-6902)
- Qian Chu (ORCID: https://orcid.org/0000-0001-8192-7630)
- Yuheng Yan
Institutions
- Shanxi Medical University (CN)
- Wuhan YZY Biopharma (China) (CN)
- Shanxi Academy of Medical Sciences (CN)
- Tongji Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1186/s13045-025-01678-2
- Citations
- 26
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 26.13
Funders
- National Natural Science Foundation of China